Research Library — Page 43 | Reta Compare
3563 research articles. Page 43 of 143.
Articles
- FDA and the 2026 Shortage Resolution Reviews
- How FDA Processes Citizen Petitions on Compounded Drugs
- FDA User Fees and Their Role in Compounded Drug Oversight
- FDA Guidance on Sterile Compounding Audits
- The FDA Safety Reporting Portal and Compounded Products
- FDA Import Refusals at the Border: Compounded GLP-1 Products
- FDA and the Federal-State Compounding Pharmacy Task Force
- FDA Approach to Compounded Peptides in Veterinary Medicine
- FDA Data Integrity Initiatives and Compounding
- Congressional Budget Requests for FDA Compounding Oversight
- Overview of Eli Lilly's Lawsuits Against Compounded Tirzepatide
- Eli Lilly v. Hims & Hers Health
- Eli Lilly v. Ro (Roman) and Affiliated Pharmacies
- Eli Lilly Sues Multiple Compounding Pharmacies in 2025
- Why Lilly Uses the Lanham Act Instead of the FDCA
- Trademark Infringement Claims in Lilly's Compounding Suits
- Lilly's False Advertising Claims Against Telehealth Operators
- State Consumer Protection Claims in Compounded GLP-1 Suits
- Preliminary Injunctions Granted in Lilly's Favor in 2025
- Lilly's Testimony Before Congress on Compounded Peptides
- Eli Lilly v. Empower Pharmacy
- Eli Lilly's Stance on 503A vs 503B Compounded Products
- Damages and Disgorgement in Lilly's Compounded Tirzepatide Cases
- Eli Lilly Cease and Desist Letters to Compounders
- Eli Lilly v. Strive Pharmacy